Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 15/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318462 | 0.83 | MAP3K5 (0.42) | MAP3K5 | |
| SCHEMBL25317556 | 0.83 | MAP3K5 (0.44) | MAP3K5 | |
| SCHEMBL28409944 | 0.80 | MAP3K5 (0.45) | MAP3K5 | |
| SCHEMBL30536002 | 0.80 | PSEN1 (0.35) | NPC1RAB9ANLRP3MAP3K5AVPR1A | |
| SCHEMBL25316646 | 0.80 | PSEN1 (0.35) | NPC1RAB9ANLRP3MAP3K5AVPR1A | |
| SCHEMBL25316032 | 0.79 | NPC1 (0.53) | NPC1RAB9ANLRP3MAP3K5 | |
| SCHEMBL30352583 | 0.74 | MAP3K5 (0.47) | NPC1RAB9ANLRP3MAP3K5 | |
| SCHEMBL28848700 | 0.74 | MAP3K5 (0.35) | NPC1RAB9ANLRP3MAP3K5GRM5 | |
| SCHEMBL25316841 | 0.74 | MAP3K5 (0.47) | NPC1RAB9ANLRP3MAP3K5 | |
| SCHEMBL21461042 | 0.68 | MAP3K5 (0.42) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| EP-4466071-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | Redx Pharma Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632845-A | Modulators of Rho-associated protein kinase (ROCK) | 莱德克斯制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | NPC1 1601/4885RAB9A 384/4885NLRP3 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.